Abstract: A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A- (CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.

Abstract: Provided is an oxygen concentration device which, as an oxygen concentration device having a reduced difference in flow rates of gas which flows through a pressure equalization valve of a pressure equalization path during a purge step and a pressure equalization step, is provided at at least one end side of the pressure equalization valve with a pressure control member having a difference in pressure loss due to the direction of gas flow so that pressure loss of the gas which flows through the pressure equalization path in one direction becomes nearly equal to that of the gas which flows therethrough in the opposite direction.

Abstract: There are provided: 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid, a sodium salt thereof and crystals of these, useful as a therapeutic agent and a prophylactic agent for gout, hyperuricemia and the like, and a method for producing the same.

Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a compressor as a device which can solve a contradictory technical problem of installing an intake sound muffler while downsizing the device under a circumstance that installation of the intake sound muffler is indispensable to reduce intake noise of the compressor, and the compressor comprises: a first lid part provided with a small hole which forms an intake port of the compressor, the lid part constituting a portion of a cylindrical casing of the compressor; a cylindrical part; and a second lid part which forms a small chamber together with the first lid part, wherein the second lid part is provided with a suction nozzle for sucking air into the small chamber.

Abstract: A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained.

Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A training apparatus includes a fixed frame, an training rod, a motor, a rotation information detection sensor, a tilt angle calculation unit, a feedback current detection unit, a position difference calculation unit, and a determination unit. The training rod tilts with at least one degree of freedom. The motor tilts the training rod. The rotation information detection sensor outputs an amount of rotation of the motor. The tilt angle calculation unit calculates a tilt angle. The feedback current detection unit detects a feedback current value. The position difference calculation unit calculates a position difference every time when a first time period elapses. The determination unit determines an error when the position difference generated during the first time period is a first threshold or higher, or when the feedback current value keeps a first current value or higher for a second time period or longer.

Abstract: The present invention is intended to provide a nose drop having high absorption of peptide hormone oxytocin or an acid addition salt thereof, or a derivative thereof through nasal mucosa and little safety concern. The present invention is a pharmaceutical composition for administration to nasal mucosa containing oxytocin or an acid addition salt thereof, or a derivative thereof and a carboxyvinyl polymer, characterized by having an osmotic pressure ratio less than 1.

Abstract: Provided is an expansion-chamber muffler as a downsized sound muffler while keeping a function of noise reduction, comprising: a tube (A) which supplies and evacuates a gas having a noise, wherein the tube (A) in the midway has a cavity with a cross-sectional area larger than that of the tube (A); and at least two or more ports for inflow or outflow of the gas on the lateral side of a tube (B) extending from the expansion-chamber muffler, on the opposite side of the noise source generating the noise.

Abstract: A compact and economical transcranial magnetic stimulation system is provided which allows patient to carry out transcranial magnetic stimulation therapy routinely and repeatedly in, for example, his or her house or a neighborhood primary-care medical facility. The system (1) has a magnetic field generating means for generating a magnetic field to be used for providing magnetic stimulation to a specific part of the patient's head. The magnetic field generating means has a magnetic coil (2) for generating a variable magnetic field, a holder (10) for holding the magnetic coil (2), cameras (150a) and another for recognizing respective reference markings (24) or specific portions of ears of the patient M (tragi (24)), and laser beam oscillators (160a) and another. According to the system, the coil (2) is set in a proper posture with respect to the specific part of the patient by aligning the optical axes of the cameras (150a) and other and the laser beam oscillators (160a) and other with respective tragi (24).

Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a congestive heart failure therapy device that applies a positive pressure within an optimal range depending on the condition of a congestive heart failure (CHF) patient. Provided is a positive pressure therapy device for congestive heart failure patients, comprising: a pressure raising unit configured to raise the pressure of air, or a gas mixture of air and other gases, to a positive pressure; an introducing unit configured to introduce the air or the gas mixture set to a positive pressure into the airways of the patient; and a blood oxygen level measurement unit configured to measure the blood oxygen level of the patient, a blood flow rate measuring unit configured to measure a blood flow rate of the patient, or a cardiac output measuring unit configured to measure a cardiac output of the patient.

Abstract: An oxygen concentration device is provided which, when the number of revolutions of a compressor reaches an upper limit of control, increases an oxygen concentration, and can extend an operating time of the oxygen concentration device, comprising a control means which controls the number of revolutions of the compressor based on a detected value of an oxygen concentration sensor, judges deterioration due to moisture absorption based on the detected value of the oxygen concentration sensor, a detected value of a pressure sensor, and an operating time of an adsorption cylinder and, when criteria for judgment of the deterioration due to moisture absorption are satisfied, makes a purge step time shorter than an initially set time.

Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

Abstract: A training apparatus includes a fixed frame, a training rod, a motor, rotation information detection sensor, tilt angle and position difference calculation units, determination, motor drive and position difference eliminating units. The training rod is supported by the fixed frame in a manner capable of being tilted by a motor about at least an X-axis or a Y-axis so as to hold the limb. The tilt angle calculation unit calculates a tilt angle of the training rod. The position difference calculation unit calculates a position difference. The determination unit obtains the position difference every time when a second time period elapses. If the position difference generated in the second time period is a first threshold or lower, the motor drive unit drives the motor so that the position difference is accumulated and maintained. The position difference eliminating unit resets the position difference at a predetermined timing.

Abstract: Provided is a training device that suppresses unintended operation of an operation rod when executing an operation mode in which the operation of the operation rod is controlled based on a force applied to the operation rod. The training device includes the operation rod, a motor, a force detection unit, a rotation information output sensor, a first command calculation unit, and a force correction unit. The operation rod moves a limb. The motor operates the operation rod in a direction of degree of freedom. The force detection unit detects a force component and outputs a force component signal. The rotation information output sensor detects an operation position of the operation rod in a corresponding direction of degree of freedom. The force correction unit calculates a corrected force component value based on the operation positions of the operation rod and the force component signal. The first command calculation unit calculates a first motor control command based on the corrected force component value.

Abstract: The purpose of the present invention is to enable the convenient supply of optimal therapeutic conditions on a per disorder and patient basis by making a coil driving power supply (1) identify the type of coil (2-1, 2-2) connected thereto and apply a specific current waveform pattern to the coil (2-1, 2-2). The transcranial magnetic stimulation system according to the present invention has one or more current waveform pattern for inducing a magnetic field in the coil, and a detection means for determining the type of the coil (2-1, 2-2) and/or a coil that is connected to the power supply (1), and determines the magnetic field inducing current waveform pattern according to the coil type determined.